

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10841AMAG	SERIAL NO. To be assigned
	APPLICANT Hylar L. Friedman, et al	
	FILING DATE Concurrently herewith	GROUP To be assigned

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
SA	WO	9	7	2	4	3	6	9	10.07.97	International	C07K	5/06		
	WO	9	8	5	8	9	4	7	30.12.98	International	C07K	5/023		
	EP	0	9	9	5	7	4	8	26.04.00	Europe	C07D	471/04		
	WO	9	8	5	8	9	4	9	30.12.98	International	C07K	5/06		
SA	EP	0	9	1	6	3	4	5	19.05.99	Europe	A61K	38/27		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SA	M. Kojima, et al., Nature, vol. 402, pp. 656-660 (9 December 1999), "Ghrelin is a growth-hormone-releasing acylated peptide from stomach."
	R.G. Smith, et al., Endocrine Reviews 18(5): 621-645 (1997), "Peptidomimetic Regulation of Growth Hormone Secretion."
	J. Svensson, et al., Hormone Research, 1999; 51(suppl 3):16-20, "Clinical and Experimental Effects of Growth Hormone Secretagogues on Various Organ Systems."
	U.S. Non-Provisional patent application Serial No. 09/649,622, filed 28 August 2000.
	W. Locke, H.D. Kirgis, C.Y. Bowers and A.A. Abdoh, Life Sci., 56: 1347-1352 (1995), "Intracerebroventricular Growth-Hormone-Releasing Peptide-6 Stimulates Eating Without Affecting Plasma Growth Hormone Responses in Rats."
	K. Okada, S. Ishii, S. Minami, H. Sugihara, T. Shibasaki and I. Wakabayashi, Endocrinology, 137: 5155-5158 (1996), "Intracerebroventricular Administration of the Growth-Hormone-Releasing Peptide KP-102 Increases Food Intake in Free-Feeding Rats."
	A. Torsello, et al., European Journal of Pharmacology 360 (1998) 123-129 (1998), "Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release."
	Greet Van den Berghe et al., J. Clin. Endocrinol. Metab. 82: 590-599, 1997, "The Somatotrophic Axis in Critical Illness: Effect of Continuous Growth Hormone (GH)-Releasing Hormone and GH-Releasing Peptide-2 Infusion."
	Greet Van den Berghe et al., J. Clin. Endocrinol. Metab. 83: 1827-1834, 1998, "Acute and Prolonged Critical Illness as Different Neuroendocrine Paradigms."
	R.C. Jenkins, R.J.M. Ross (eds): The Endocrine Response to Acute Illness. Front. Horm. Res. Basel, Karger, 1999. Vol. 24, pp. 152-175, "The Regulation of Growth Hormone Secretion."
	M. Ankersen, et al., Drug Discovery Today, Vol. 4, No. 11, November 1999, pages 497-506, "Growth hormone secretagogues: recent advances and applications."
	F.F. Casanueva, et al., TEM Vol. 10, No. 1, 1999, pages 30-38, "Growth Hormone Secretagogues: Physiological Role and Clinical Utility."
SA	M.G. Murphy, et al., J. Clin. Endocrinol. Metab. 83: 320-325, 1998, "MK-677, an Orally Active Growth Hormone Secretagogue,

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC10841AMAG	SERIAL NO. To be assigned
		APPLICANT Hylar L. Friedman, et al	
		FILING DATE Concurrently herewith	GROUP To be assigned
		Reverses Diet-Induced Catabolism."	
SA		M.B. Andersen, et al., Third International Symposium on Growth Hormone Secretagogues, February 17-19, 2000, Keystone Resort Colorado, "Growth hormone secretagogues increase food intake in non-deprived rats."	
SA		I. Ahnfelt-Rønne, et al., Third International Symposium on Growth Hormone Secretagogues, February 17-19, 2000, Keystone Resort Colorado, "Progress in New GH Secretagogue Product Development."	
EXAMINER  DATE CONSIDERED 11/1/02			
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

